Compare MobilEye Global Inc (MBLY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs 10X Genomics Inc — how do they compare? MobilEye Global Inc trades at $7.2 (market cap $6.00B), while 10X Genomics Inc trades at $81.65 (market cap $10.07B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and 10X Genomics Inc for 92 Days on average.
| MBLY | TXG | |
|---|---|---|
Market Cap | $6.00B | $10.07B |
Volume | 7,007,849 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $97.74 |
52-Week Low | $6.56 | $11.48 |
Typical Hold Time | 15 Days | 92 Days |
Enterprise Value | $4.56B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.14, down 0.14% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $2.0B in 2026 but faces significant profitability challenges with a -201.49% net income margin. Analyst consensus is mixed with 57.7% buy ratings but a bearish technical outlook from indicators.
The stock presents a high-risk opportunity with substantial upside to the $10.83 consensus target but requires careful monitoring of profitability improvements. Key risks include persistent losses, competitive pressures in autonomous driving, and execution challenges in robotaxi expansion.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
